fls.txt



item1.txt
The accompanying consolidated financial statements, in the opinion of management, include all adjustments, consisting of normal recurring accruals, necessary for a fair presentation of the results for the interim periods presented.
The Company’s results for the three-month periods ended December 31, 2017 are not necessarily indicative of the results for the entire 2018 fiscal year.
There were 337,325 non-vested shares outstanding as of December 31, 2017.
EBIT on a consolidated basis is a non-GAAP financial measure.
Furthermore, the use of non-GAAP financial measures is not intended to replace any measures of performance determined in accordance with GAAP.
The Credit Facility includes a $450 million revolving line of credit as well as provisions allowing for the increase of the facility commitment amount by an additional $250 million, if necessary, with the consent of the lenders.
The bank syndication supporting the facility is comprised of a diverse group of nine banks led by JPMorgan Chase Bank, N.A., as Administrative Agent.
The Credit Facility requires, as determined by certain financial ratios, a facility fee ranging from 12.5 to 27.5 basis points per year on the unused portion.
The terms of the facility provide that interest on borrowings may be calculated at a spread over the London Interbank Offered Rate (LIBOR) or based on the prime rate, at the Company’s election.
The financial covenants of the Credit Facility include a leverage ratio and an interest coverage ratio.
118 (SAB 118) was issued by the SEC effective December 22, 2017.
SAB 118 allows registrants to record provisional amounts of the income tax effects of the TCJA where the information necessary to complete the accounting under ASC Topic 740 is not available but the amounts are based on reasonable estimates.
SAB 118 permits registrants to record adjustments to its provisional amounts during the measurement period (which cannot exceed one year).


item2.txt
In the first quarter of 2018, sales, net earnings and diluted earnings per share were $173.5 million, $34.7 million and $1.33 per share, respectively, compared to $146.4 million, $10.7 million and $0.41 per share, respectively, in the first quarter of 2017.
Net sales increased $27.1 million, or 18.5%, to $173.5 million in the first quarter of 2018 from $146.4 million in the first quarter of 2017.
The increase in net sales in the first quarter of 2018 as compared to the first quarter of 2017 was due to a $20.2 million increase in the USG segment, a $3.7 million increase in the Test segment, a $2.0 million increase in the Technical Packaging segment and a $1.2 million increase in the Filtration segment.
In the first quarter of 2018, net sales of $37.5 million were $3.7 million, or 10.9%, higher than the $33.8 million recorded in the first quarter of 2017.
In the first quarter of 2018, net sales of $20.2 million were $2.0 million, or 10.9% higher than the $18.2 million recorded in the first quarter of 2017.
The increase in the first quarter of 2018 compared to the first quarter of 2017 was mainly due to a $1.1 million increase in net sales at TEQ due to higher shipments to medical customers and a $0.9 million increase in net sales at Plastique.
Backlog was $404.1 million at December 31, 2017 compared with $377.1 million at September 30, 2017.
The increase in amortization expense in the first quarter of 2018 compared to the first quarter of 2017 was mainly due to an increase in amortization of intangibles related to the Morgan Schaffer, NRG, and Mayday acquisitions.
There were no significant items in other expenses, net, in the first quarter of 2018.
The Company evaluates the performance of its operating segments based on EBIT, and provides EBIT on a consolidated basis, which is a non-GAAP financial measure.
Please refer to the discussion of non-GAAP financial measures in Note 6 to the Consolidated Financial Statements, above.
Corporate costs included in EBIT were $8.9 million and $7.0 million in the first quarter of 2018 and 2017, respectively.
The increase in Corporate costs in the first quarter of 2018 compared to the first quarter of 2017 was primarily due to higher professional fees and an increase in amortization of intangible assets related to recent acquisitions.
The TCJA includes a tax on global intangible low-taxed income (“GILTI”).
Because there are interpretative questions associated with the approach that involves recognizing deferred taxes, the Company will undertake an evaluation of these questions and make the accounting policy election during the SAB 118 measurement period.


item3.txt
All derivative instruments are reported on the balance sheet at fair value.


item4.txt



